Athenex (ATNX) Downgraded by BidaskClub to Sell

BidaskClub downgraded shares of Athenex (NASDAQ:ATNX) from a hold rating to a sell rating in a report released on Thursday morning.

ATNX has been the subject of a number of other reports. JPMorgan Chase & Co. began coverage on shares of Athenex in a report on Wednesday, October 18th. They set a neutral rating and a $22.20 price objective for the company. Laidlaw began coverage on shares of Athenex in a report on Tuesday, September 19th. They set a buy rating and a $36.00 price objective for the company. Credit Suisse Group initiated coverage on shares of Athenex in a report on Monday, September 18th. They set an outperform rating and a $25.00 price objective for the company. Finally, Royal Bank of Canada initiated coverage on shares of Athenex in a report on Thursday, September 14th. They set an outperform rating and a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $27.64.

Shares of Athenex (ATNX) traded down $0.33 during midday trading on Thursday, hitting $15.61. 73,000 shares of the stock were exchanged, compared to its average volume of 150,967. The firm has a market capitalization of $904.73 and a PE ratio of -5.66. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79.

A number of hedge funds have recently made changes to their positions in ATNX. California State Teachers Retirement System bought a new stake in Athenex in the third quarter worth about $198,000. Bank of New York Mellon Corp bought a new stake in shares of Athenex in the second quarter valued at approximately $240,000. Tudor Investment Corp ET AL bought a new stake in shares of Athenex in the second quarter valued at approximately $320,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Athenex in the third quarter valued at approximately $524,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Athenex in the second quarter valued at approximately $601,000. 2.93% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3127565/athenex-atnx-downgraded-by-bidaskclub-to-sell.html.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.